Abbott to Sell ALK's House Dust Mite Sublingual Allergy Immunotherapy Tablet in SE Asia

ALK (OTC: AKBLF) today announced an expansion of its partnership with Abbott under which Abbott will register and sell ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX(r) in Europe) in seven new growth markets in South-East Asia.  Under the terms of the deal, Abbott gains exclusive rights to register, promote and distribute the product in Hong Kong, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand. ALK and Abbott will share the revenue generated in the territory where ALK will be responsible for product supply to Abbott.  Regulatory submissions in the new markets are expected to be based upon ALK's regulatory filing which was approved by European authorities in August 2015. As a result, the first launches in South-East Asia are expected to take place from 2017 onwards.  Since 2014, Abbott has had exclusive rights to commercialise ALK's SLIT-tablets covering HDM, grass, ragweed and tree allergies in Russia and other surrounding countries.  Flemming Pedersen, EVP and CFO of ALK, said: "This new agreement between ALK and Abbott continues our strategic progress as we expand our commercial reach and work to globalise our most important new product See full press release